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Clinically isolated syndrome (CIs) is the earliest clinical episode in multiple sclerosis (Ms). Low 
environmental exposure to UV radiation is implicated in risk of developing Ms, and therefore, 
narrowband UVB phototherapy might delay progression to Ms in people with CIs. twenty individuals 
with CIS were recruited, and half were randomised to receive 24 sessions of narrowband UVB 
phototherapy over a period of 8 weeks. Here, the effects of narrowband UVB phototherapy on the 
frequencies of circulating immune cells and immunoglobulin levels after phototherapy are reported. 
Peripheral blood samples for all participants were collected at baseline, and 1, 2, 3, 6 and 12 months 
after enrolment. An extensive panel of leukocyte populations, including subsets of t cells, B cells, 
monocytes, dendritic cells, and natural killer cells were examined in phototherapy-treated and 
control participants, and immunoglobulin levels measured in serum. There were significant short-
term increases in the frequency of naïve B cells, intermediate monocytes, and fraction III FoxP3+ t 
regulatory cells, and decreases in switched memory B cells and classical monocytes in phototherapy-
treated individuals. Since B cells are increasingly targeted by MS therapies, the effects of narrowband 
UVB phototherapy in people with Ms should be investigated further.
UV radiation (UVR) has a number of effects on local and systemic immunity. Evidence from mouse studies shows 
that exposure to sub-erythemal UVR suppresses immune responses to topically applied experimental antigens 
that are taken up by Langerhans cells and dermal dendritic cells (DCs) and transferred to draining lymph nodes, 
inducing the generation of T-regulatory (Treg) cells. This process is assisted by UVR-induced immunoregulatory 
cytokines, neuropeptides and products of other pathways, including the vitamin D pathway, activated by UVR 
[reviewed in1,2]. Other immunoregulatory cells have also been implicated in UVR-induced immunosuppression, 
including regulatory B cells (Bregs)3, bone marrow-derived DCs4 and macrophages5, mast cells6 and NK cells7.
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UVR immunoregulation has also been confirmed in humans, with UVR exposure causing reduced responses 
to antigens applied to both UV-irradiated and non-irradiated skin2. However, the mechanisms by which UVR 
may stimulate systemic immunosuppression in humans, and whether UVR exposure can be used to halt or mod-
ulate the progression of an immune-mediated disease such as multiple sclerosis (MS), are less clear. Narrowband 
UVB delivered to lesional skin is a mainstay of treatment for psoriasis, with UV-induced immunoregulatory cir-
cuits thought to operate locally8, although systemic effects are also observed. In humans exposed multiple times 
to sub-erythemal narrowband UVB, there have been varied and contradictory reports of increased numbers of 
circulating Tregs9–12. A reduced frequency of circulating NK cells has also been reported in humans following 
multiple sub-erythemal UVB exposures7,13.
MS is an inflammatory neurological condition, and though a number of genetic and environmental risk fac-
tors have been implicated in the onset of MS, fewer factors are known to affect disease activity and progression. 
However, low lifetime environmental UVR exposure prior to the first evidence of demyelination has been associ-
ated with a more rapid transition to MS and more relapses14. Since clinically isolated syndrome (CIS) is the ear-
liest clinical episode in the MS pathway, patients with CIS were chosen for participation in a trial of narrowband 
UVB phototherapy, which aimed to prevent the progression of CIS to MS (the PhoCIS trial). This research group 
has previously reported that people with CIS, in comparison to healthy controls, have an imbalance in the propor-
tion of suppressive “fraction I” (FrI) and non-suppressive FrIII FoxP3+ Treg cells, together with lower expression 
of Helios, a transcription factor responsible for stabilising Treg suppressive function15. People with CIS also have 
more transitional B cells, CD141+ myeloid DCs and, if just diagnosed (<14 days), more CD56hi NK cells15,16.
The clinical outcomes of the PhoCIS trial were previously reported, with a non-significant reduction in MS 
observed at 12 months in the phototherapy-treated group compared with controls17. The current study investi-
gated whether the frequencies of peripheral blood mononuclear cell (PBMC) subsets or serum immunoglobulins 
were altered by narrowband UVB phototherapy in the same cohort. PBMCs were collected from participants 
at the time of their recruitment, and after 1, 2, 3, 6 and 12 months on study. However, since a high proportion 
of participants commenced disease modifying therapies during follow-up, cellular and immunoglobulin data 
were analysed to 3 months only. At completion of the phototherapy intervention, there was a significantly higher 
frequency with phototherapy of naïve B cells, intermediate monocytes, and FrIII Tregs, and a significantly lower 
frequency of classical monocytes and switched memory (SM) B cells in phototherapy-treated participants com-
pared with controls. These effects on PBMC populations were short-term, and one month after phototherapy was 
ceased, no significant effects of the intervention were detected.
Methods
study participants. Recruitment for this study was conducted in Perth, Western Australia (32°S). The trial 
design18, CONSORT diagram17, and clinical outcomes17 have been published elsewhere. Briefly, 20 individuals 
presenting with CIS within 120 days, and meeting PatyA or PatyB criteria based on magnetic resonance imaging 
(MRI), were included. The biological and clinical characteristics of the participants at enrolment were similar 
between groups, except that there were more males in the phototherapy group17. If participants did not have 
serum 25(OH)-vitamin D3 [25(OH)D]levels > 80 nmol/L at enrolment, they were supplemented with oral vita-
min D (n = 7; two in the phototherapy group and five in the non-phototherapy group)17. As previously reported17, 
there were no differences in serum 25(OH)D levels between groups at baseline. Phototherapy, and not extra sup-
plementation, increased serum 25(OH)D levels after 2 and 3 months on study, and this increase was independent 
of season17.
MRI scans and medical reviews were performed at 3, 6, and 12 months. All participants (100%) in the con-
trol group converted to MS within 12 months of study enrolment, compared with 7 (70%) in the phototherapy 
group17.
This study was carried out in accordance with the recommendations of the National Health and Medical 
Research Council of Australia’s National Statement on Ethical Conduct in Human Research. The PhoCIS study 
protocol was approved by the Bellberry Human Research Ethics committee (2014-02-083) and endorsed by the 
Human Research Ethics Office of the University of Western Australia (RA/4/1/6796). The trial was registered with 
the Australian and New Zealand Clinical Trials Registry (ACTRN 12614000185662, registered on 19/02/2014). 
All participants gave written informed consent in accordance with the Declaration of Helsinki prior to study 
procedures being performed.
phototherapy intervention. Participants with CIS were randomised to receive, or not receive (controls), 
narrowband UVB phototherapy. Those randomised to the intervention group received narrowband UVB photo-
therapy three times per week for the first 8 weeks (24 sessions in total). Phototherapy was delivered according to 
the Dundee protocol, based on patient skin type, as previously described17,18.
Blood sampling. Peripheral venous blood was collected at baseline (B), 1 month (1 M), 2 months (2 M), 3 
months (3 M), 6 months (6 M) and 12 months (12 M) post-enrolment. There were 10 participants recruited to 
each group (phototherapy and control), but one control participant was lost to follow up after one week, and 
therefore could not be included in this longitudinal study. Although most follow-up samples were collected for 
the remaining participants, there were a small number of samples not collected. The reasons for missing sample 
collection included when participants were not able to attend appointments (n = 7 samples missed), withdrawal 
from the blood collection part of the study due to anxiety (n = 4 samples missed), and relocation to another 
state following completion of phototherapy (n = 2 samples missed). In total, 101 blood samples were collected 
(Table 1). There was no significant difference between the two study arms in the number of missing samples at 
each time point (not shown).
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Serum 25(OH)D levels. Serum 25(OH)-vitamin D3 [25(OH)D] was measured by liquid chromatography 
tandem mass spectrometry, as previously described19. As expected, serum 25(OH)D levels were significantly 
lower in the winter months, and significantly higher in individuals undergoing phototherapy compared with the 
controls at 2 M and 3M17. Since higher serum 25(OH)D levels were a characteristic of the phototherapy group, 
collinearity between the at-visit 25(OH)D outcome variable and the phototherapy group indicated that at-visit 
25(OH)D level was not an appropriate covariate to include in data models. Therefore, baseline serum 25(OH)D 
level was instead included as a covariate in all data models.
Measurement of serum immunoglobulins. We previously reported an association between higher 
serum immunoglobulin (Ig)G3 levels, or IgG3 as a percent of total IgG, and a rapid conversion from CIS to MS20. 
Therefore, whether phototherapy had any effect on the levels of serum Ig levels was investigated. Total IgG, IgA, 
IgM, and IgG1–4 subclasses were measured in serum samples collected between baseline and the 6 M time point 
(n = 81) using cytometric bead arrays, as previously described20. These data were used to calculate the absolute 
concentrations of Ig (µg/mL) and IgG subclasses as a proportion of total IgG (%IgG). All time points when sera 
were examined had corresponding PBMC samples tested by flow cytometry.
participant use of disease modifying therapies. At enrolment, all participants were drug naïve and had 
not received steroids within the past 30 days. However, within the study period of 12 M, many participants con-
verted from CIS to MS17 and began disease modifying therapies (DMTs; Table 1). DMT use was not significantly 
different between the control and phototherapy groups at the different sampling time points (Table 1). Given the 
diversity of DMTs prescribed, it was not possible to compare the effects of specific DMTs on cell frequencies. 
Preliminary attempts to include the use of DMTs within 30 days of the blood collection as an additional covariate 
in data analyses indicated significant collinearity of DMT use with the treatment variable, particularly during the 
latter time points of the study. Therefore, blood samples from the 6 M and 12 M time points were excluded from 
analyses, since the effects of DMTs could not be adequately accounted for. Although a small number of individ-
uals included in analyses had been treated with DMTs at the 2 M and 3 M time points, the majority of samples 
included in the longitudinal analyses were collected from drug-naïve individuals.
Flow cytometry for identification of subsets in peripheral blood mononuclear cells. PBMCs 
were isolated from heparinised blood and extensive cellular phenotyping by flow cytometry performed as previ-
ously described15,16.
The full list of cell phenotypes investigated are listed in Table 2. T cells, B cells, monocytes, dendritic cells 
(DCs), natural killer (NK) cells, natural killer T (NKT) cells, and presumed γδT cells were all examined as a 
percent of total PBMC. In addition, B cell, monocyte, DC and NK cell subsets were examined as previously 
described16.
B cell subsets were examined as a percent of total CD19+ B cells, including CD19+CD20− plas-
mablasts (CD38+CD27+CD24-IgD−), and the CD19+CD20+ cell subsets including naïve B cells 
(CD27-IgD+CD38lo/−CD24lo–hi), transitional B cells (CD27-IgD+CD38+ CD24hi), double negative 
(IgD-CD27−) B cells, non-switched memory (NSM) B cells (CD27+IgD+), and switched memory (SM) B cells 
(CD27+IgD−)16.
Monocyte subsets were examined as a percent of total monocytes, including classical mono-
cytes (CD14+CD16lo/−), intermediate monocytes (CD14+CD16int) and non-classical monocytes 
(CD14loCD16+)16.
DCs subsets were examined as a percent of total DCs, including CD141+ myeloid DCs, CD1c+ myeloid DCs, 
and CD303+ plasmacytoid DCs (pDCs)16.
NK cell subsets were examined as a percent of total NK cells, including CD56hiCD16lo NK cells, 
CD56hiCD16int NK cells, CD56loCD16hi NK cells, CD56loCD16hiCD57+ NK cells, and CD56loCD16hiCD57- 
NK cells16.
T regulatory cells (Tregs) and follicular Tregs (Tfr) were identified as CD3+CD4+FoxP3+ cells, with the lat-
ter also expressing CXCR5. Tregs were further categorised into resting (FrI), activated (FrII) and non-suppressive 
(FrIII) fractions based on relative expression of FoxP3 and CD45RA, and as Helios+/− as previously described15.
In addition to our gating panels that were previously published15,16, T cells were identified in PBMC by flow 
cytometry using mouse anti-human surface marker antibodies against CD3 (FITC clone UCHT1), CD4 (APC-H7 
Time point No phototherapy Phototherapy
Baseline 10 (0) 10 (0)
1 month 4 (0) 9 (0)
2 months 7 (1)+ 9 (0)
3 months 9 (1)# 10 (3)++*
6 months 8 (4)#++* 9 (3)+**
12 months 8 (7)##+++** 9 (4)+***
Table 1. Number of PBMC samples collected during the study. The number of samples collected from donors 
treated within 30 days with disease modifying therapies (DMTs) at that time point are shown in brackets. 
Superscript symbols indicate the prescribed DMT for each individual: #fingolimod; +dimethyl fumarate; 
*natalizumab; the count of symbols indicates the number of participants at that time point taking the DMT.
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clone RPA-T4), CD8 (PE-CF594 clone RPA-T8), CD25 (PE-Cy7 clone M-A251), CD27 (BV421 clone M-T271), 
CD45RA (APC clone H100), CD45RO (AF700 clone UCHL1), CD127 (BV786 clone HIL-7R-M21), purchased 
from BD Biosciences (North Ryde, Australia) and data collected using the BD LSR Fortessa flow cytometer and 
analysed using FlowJo software, as previously described16. Tregs were classified according to the traditional defi-
nition of CD25+ CD127lo/neg. Traditional Tregs were further characterised as naïve (CD45RA+) or memory 
(CD45RO+) phenotypes. CD4+ or CD8+ cells were defined as naïve, effector, central memory (CM) or effector 
memory (EM) T cells, according to the gating strategy shown in Fig. 1.
This approach, which included two different definitions of Tregs (FoxP3+ or traditional CD25+CD127lo 
Tregs), allowed us to make comparisons of our findings to other reports, that may utilise either of these gating 
strategies.
statistical methods. Differences in categorical outcomes including number of samples affected by DMT 
use and sex of participants between phototherapy and no phototherapy (control) participant groups at each 
time point were compared using Fisher’s exact test. Cell frequencies at baseline and at subsequent visits in either 
phototherapy or control groups were compared using Wilcoxon signed-rank tests. Differences in cell frequen-
cies between groups at specific time points were tested using Mann-Whitney U tests, which showed that the 
study groups had significantly different frequencies of NKT cells (%PBMC), CD1c+ DCs (%DC), CD141+ DCs 
(%DC), pDC (%DC), and CD56hiCD16int NK cells (%NK) at baseline. Therefore, all preliminary analyses com-
paring phototherapy and control participants factored in individual baseline cell frequencies, with data analysed 
as percent change (Δ) from baseline, using the calculation ((value-baseline)/baseline) × 100.
Given the vast number of cell types measured across many timepoints, an a priori structured approach to 
hypothesis testing was defined to guide the exploratory analysis in the aim of limiting the number of compar-
isons to be made and reported on. This involved examining the changes in each cell subset over the follow-up 
period with Mann-Whitney U tests to detect between-group differences or Wilcoxon signed-rank tests to detect 
time-dependent effects; where a difference was observed (p < 0.1), the basic difference analysis was superseded 
by the more comprehensive modelling described below (applied to cell phenotypes indicated with an asterisk in 
Table 2).
Linear mixed effects models with fixed and random effects (random intercept per participant) were used to 
investigate the longitudinal effects of phototherapy on cell frequencies and serum Ig levels across the follow-up 
period, controlling for baseline levels as a covariable. All participants with at least one additional sample collected 
after baseline were included in the analysis. Models were adjusted for age (years), sex, baseline serum 25(OH)D 
levels (nmol/L), and duration of time on study (days). The 1–2 M mixed effects model incorporated the 1 M and 
2 M data, and the 1–3 M mixed effects model incorporated all of the 1 M, 2 M and 3 M data (n = 29 and n = 38 
total samples from the control and phototherapy groups, respectively) (Tables 3 and 4).
Subsequently, to determine whether phototherapy group differences observed in longitudinal data models 
occurred at specific study time points, the effects of phototherapy on cell frequencies were investigated at 2 M and 
3 M using two separate models of linear regression (ANCOVA framework) (Tables 5 and 6). Model 1 investigated 
cell frequency differences between groups at each time point adjusting for baseline cell frequency levels as a 
covariable. A second linear regression model was used (Model 2), adjusting for the baseline levels of cell frequen-
cies as a covariable, as well as age, sex, and baseline serum 25(OH)D levels. The 1 M time point was excluded from 
linear regression analyses to avoid any bias introduced by the (non-significant) difference in sample numbers 
between treatment groups at this time point. Where appropriate, models were examined with the inclusion of an 
indicator term for DMT status, however the inclusion of this term had little impact on the coefficients of interest 
so models without this term are reported.
All statistical analyses were performed using SPSS software (v25, IBM corp.), and appropriateness of model fit 
was determined by visual inspection of diagnostic residual plots. In all analyses, a p-value < 0.05 was considered 
statistically significant.
PBMCs T cells CD4+ T cells Tregs
CD8+ T 

























































Table 2. Description of cell types examined in phototherapy-treated and control individuals. Cells were 
quantified by flow cytometry as a frequency of the cell type in the bolded header row above that cell population. 
An asterisk indicates a cell type that was tested for effects of phototherapy in mixed effects models and linear 
regression.
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Results
Effect of narrowband UVB phototherapy treatment on cell frequencies. T cell frequencies. There 
was no association of phototherapy with the frequency of CD4+ or CD8+ T cells, CD4+ Foxp3+ Tregs or Tfr, 
or CD4+CD25+CD127lo traditional Tregs as a percent of PBMCs (data not shown). There was no association of 
phototherapy with the proportion of FoxP3+ Tregs expressing Helios.
Phototherapy was associated with a significantly higher frequency of non-suppressive FrIII cells as a propor-
tion of the total CD4+FoxP3+CXCR5− Tregs in the 1–3 M model (Table 4; p = 0.044). Non-significant increases 
in FrIII cells were associated with phototherapy in the 1–2 M model (Table 3, p = 0.07) and at 3 M in linear regres-
sion models prior to adjusting for other variables (p = 0.09) but not after accounting for age, sex, and baseline 
25(OH)D levels (p = 0.21) (Table 6).
In summary, the frequency of the FrIII Treg population was higher in those who received phototherapy, but no 
other effects on T cells, particularly immunosuppressive CD4+ Tregs, were observed in this study. The frequen-
cies of FrIII Tregs at each time point as a percent shift from individual baseline frequencies are shown in Fig. 2.
B cell frequencies. There were no significant effects of phototherapy on total CD19+ B cell frequencies as a percent 
of total PBMC. Phototherapy was associated with higher naïve B cell frequencies as a percent of all B cells in both the 
Figure 1. T cell gating strategy applied to data acquired using flow cytometry. T cells from freshly isolated 
PBMC from study participants were included after gating on PBMC using FSC and SSC, and CD3+ cells. CD3+ 
cells were differentiated using CD8 versus CD4 plots into CD4+ and CD8+ T cells (not shown). (a) CD4+ T 
cells were separated into Tregs (CD25+CD127lo/neg) and other cells. (b) Tregs identified in panel (a) were further 
classified as naïve (CD45RA+) or memory phenotypes (CD45RO+). (c) Non-Tregs identified in panel (a) were 
classified as central memory (CM) CD4+ T cells (CD27+CD45RA−), naïve CD4+ T cells (CD27+CD45RA+), 
effector memory (EM) CD4+ T cells (CD27−CD45RA−) and effector CD4+ T cells (CD27-CD45RA+). (d) 
CD8+ T cells were separated into central memory (CM) CD8+ T cells (CD27+CD45RA−), naïve CD8+ T 
cells (CD27+CD45RA+), effector memory (EM) CD8+ T cells (CD27−CD45RA−) and effector CD8+ T cells 
(CD27−CD45RA+).
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1–2 M and 1–3 M models (Tables 3 and 4). Significant differences were observed at 2 M only (in both the adjusted 
and unadjusted models). By 3 M, the effect of phototherapy was non-significant (p = 0.063) (Tables 5 and 6). 
These findings together indicate that phototherapy was associated with a short-term effect on the frequency of 
naïve B cells.
Phototherapy was associated with significantly lower SM B cell frequencies (as a percent of all B cells) in 
the 1–3 M models (Table 4), but not when including only the 1–2 M data (Table 3). Phototherapy was associated 
with non-significantly lower SM B cell frequencies at 2 M (Table 5) and 3M (Table 6).
The frequencies of the B cell populations that were found to be significantly different between treatment 
groups in mixed effects models are shown in Fig. 3.
In summary, phototherapy was associated with significantly higher naïve B cell frequencies and significantly 
lower SM B cell frequencies, but these effects were not detected at the 3 M time point (one month after photother-
apy treatment had completed).
Monocyte frequencies. There was no significant association between phototherapy and total monocyte frequen-
cies as a percent of total PBMC. Phototherapy was associated with a significantly lower frequency of classical 
monocytes as a percent of monocytes in the 1–2 M and 1–3 M models (Tables 3 and 4).
Phototherapy was also associated with a significantly higher frequency of intermediate monocytes in the 
1–2 M phototherapy treatment period (Table 3), but this effect was not significant in the 1–3 M model.
The short-term effects of phototherapy on monocyte subset frequencies were confirmed by linear regression 
models at 2 M, which showed that classical monocyte frequency was significantly lower, and intermediate mono-
cyte frequency significantly higher, in phototherapy-treated individuals at this time point (Table 6). However, 
these effects were not present in the 3 M assessment.
In summary, phototherapy was associated with lower classical monocyte frequencies compared to controls 
and higher frequencies of intermediate monocytes, but only during the phototherapy treatment period. The 
change from individual baseline cell frequency for classical and intermediate monocytes are shown in Fig. 4.





Female sex 4.256 −0.818 9.331 0.096
Phototherapy 3.619 −0.351 7.588 0.072
Baseline 25(OH)D −0.0123 −0.0694 0.0448 0.658
Time on study −0.0542 −0.152 0.0436 0.262
Age 0.0561 −0.183 0.295 0.630
Naïve B cells (%B cells)
Female sex 2.463 −3.64 8.567 0.412
Phototherapy 8.263 1.80 14.722 0.015
Baseline 25(OH)D 0.128 0.033 0.224 0.010
Time on study −0.08 −0.26 0.095 0.355
Age −0.086 −0.470 0.302 0.652
Switched memory (SM) 
B cells (%B cells)
Female sex −0.276 −3.530 2.979 0.862
Phototherapy −2.154 −5.481 1.173 0.193
Baseline 25(OH)D −0.04 −0.091 0.010 0.110
Time on study 0.043 −0.048 0.135 0.337
Age 0.003 −0.196 0.201 0.976
Classical monocytes 
(%monocytes)
Female sex −4.056 −9.779 1.667 0.156
Phototherapy −7.061 −13.046 −1.075 0.023
Baseline 25(OH)D 0.082 −0.005 0.169 0.064
Time on study 0.042 −0.114 0.198 0.583




Female sex 1.757 −0.462 3.976 0.115
Phototherapy 2.903 0.683 5.123 0.013
Baseline 25(OH)D −0.021 −0.055 0.013 0.222
Time on study 0.025 −0.036 0.086 0.406
Age 0.101 −0.036 0.237 0.140
Table 3. Effects of UVB phototherapy on cell frequencies during treatment using data from 1–2 M, adjusted for 
relevant covariables. Results are from mixed effect models of longitudinal data. Statistically significant p-values 
are shown in bolded font. *Data from 1–2 M time points were examined using linear mixed effects models. 
Phototherapy and sex were included in models as binary outcome variables. Baseline 25(OH)D (nmol/L), 
time on study (days) and age (years), as well as baseline cell frequency (not shown in Table) were included as 
continuous variables in the statistical models.
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NK cell frequencies. Phototherapy was not associated with changes in total NK cell frequencies as a percent of 
total PBMC, or subset composition as a percent of NK cells in mixed effects models or linear regression models 
at any time point.
DC frequencies. The frequency of total DCs as a percent of total PBMC, or DC subsets as a percent of total DC 
were not significantly different between control and phototherapy groups.
Effects of phototherapy on serum Ig levels. There were no significant effects of phototherapy on the 
serum levels of total IgG, IgA, IgM, or IgG1–4 subclasses, or the proportions of IgG1–4 as a percent of total IgG 
in either 1–2 M or 1–3 M mixed effects models (data not shown).
Discussion
The PhoCIS trial aimed to harness the immunoregulatory effects of narrowband UVB radiation to modulate the 
disease course in individuals with high-risk CIS18. In this study, UVB phototherapy was associated with signif-
icantly higher circulating frequency of naïve B cells as a percent of B cells, intermediate monocytes as a percent 
of monocytes, and non-suppressive FrIII Tregs as a percent of Tregs, and significantly lower frequencies of SM 
B cells as a percent of B cells and classical monocytes as a percent of monocytes, compared with controls. The 
effects of the eight weeks of phototherapy were short-lived, and when examined at specific time points using 
linear regression, effects of phototherapy were observed at the 2 M sample collection point, but not at the 3 M 
collection point.
The narrowband UVB intervention was associated with significant changes in the frequencies of naïve and 
SM B cells in the UVB-irradiated individuals, whose levels after treatment were significantly higher and lower, 
respectively, compared with the controls. To our knowledge, this is the first report of such effects on these B cell 
subsets in human blood. Although this is the first trial of narrowband UVB phototherapy for CIS, in people with 
psoriasis for whom this treatment has been a mainstay, UVB exposure decreases the levels in skin of inflamma-
tory cytokines such as TNF-α, IFN-γ, and IL-17, that may influence B cell maturation21–23. Although we have 
not investigated cellular function here, in general, naïve B cells are less responsive to signals that stimulate cell 
proliferation, Ig secretion and survival than memory B cells due to differentially expressed immunomodulatory 





Female sex 1.499 −3.229 6.226 0.525
Phototherapy 3.760 0.107 7.413 0.044
Baseline 25(OH)D −0.0567 −0.115 0.00198 0.058
Time on study −0.0489 −0.108 0.0105 0.104
Age 0.115 −0.118 0.347 0.325
Naïve B cells (%B cells)
Female sex 5.254 −0.268 10.776 0.062
Phototherapy 9.339 3.773 14.905 0.002
Baseline 25(OH)D 0.138 0.051 0.226 0.003
Time on study −0.071 −0.166 0.023 0.136
Age −0.309 −0.659 0.041 0.082
Switched memory (SM) 
B cells (%B cells)
Female sex −1.268 −3.754 1.218 0.309
Phototherapy −3.175 −5.643 −0.707 0.013
Baseline 25(OH)D −0.05 −0.089 −0.011 0.014
Time on study 0.031 −0.012 0.074 0.151
Age 0.015 −0.137 0.167 0.844
Classical monocytes 
(%monocytes)
Female sex −3.026 −7.239 1.187 0.155
Phototherapy −5.557 −9.92 −1.195 0.014
Baseline 25(OH)D 0.052 −0.014 0.117 0.120
Time on study 0.034 −0.038 0.105 0.348




Female sex 0.931 −1.063 2.925 0.351
Phototherapy 1.779 −0.183 3.742 0.074
Baseline 25(OH)D −0.025 −0.056 0.007 0.120
Time on study 0.012 −0.022 0.046 0.471
Age 0.065 −0.058 0.189 0.292
Table 4. Effects of UVB phototherapy on cell frequencies both during and at 1 month after treatment, using 
data from 1–3 M, adjusted for relevant covariables. Results are from mixed effects models using longitudinal 
data. Statistically significant p-values are shown in bolded font. *Data from 1– 3 M time points were examined 
using linear mixed effects models. Phototherapy and sex were included in models as binary outcome variables. 
Baseline 25(OH)D (nmol/L), time on study (days) and age (years), as well as baseline cell frequency (not shown 
in Table) were included as continuous variables in the statistical models.













Phototherapy 2.781 2.154 0.221 4.545 2.88 0.149
Age 0.179 0.171 0.323
Sex −3.624 3.638 0.345
Baseline 25(OH)D −0.01 0.042 0.817
Naïve B cells (%B 
cells)
Phototherapy 11.236 4.129 0.017 13.669 4.648 0.015
Age −0.054 0.309 0.864
Sex −5.023 4.670 0.307
Baseline 25(OH)D 0.157 0.075 0.061
Switched memory 
(SM) B cells (%B 
cells)
Phototherapy −3.806 2.147 0.10 −5.097 2.623 0.081
Age −0.019 0.164 0.911
Sex 2.730 2.624 0.323




Phototherapy −7.248 3.376 0.051 −9.590 4.183 0.045
Age 0.058 0.250 0.821
Sex 3.925 4.002 0.350




Phototherapy 3.595 1.456 0.028 4.114 1.74 0.040
Age 0.122 0.111 0.300
Sex −1.661 1.728 0.359
Baseline 25(OH)D −0.027 0.027 0.350
Table 5. Changes from baseline cell frequencies at the 2 month time point. Results were obtained using linear 
regression models. Statistically significant p-values are shown in bolded font. *Table shows unstandardised 
coefficients. All models were adjusted for participant’s baseline cell frequencies. ^Model 1 = linear regression for 
effects of phototherapy (categorical variable) adjusted for baseline cell frequencies. #Model 2 = linear regression 













Phototherapy 5.562 3.078 0.09 4.517 3.417 0.209
Age 0.239 0.234 0.326
Sex 2.384 4.468 0.603
Baseline 25(OH)D −0.132 0.063 0.056
Naïve B cells (%B 
cells)
Phototherapy 5.009 5.006 0.332 11.054 5.427 0.063
Age −0.685 0.366 0.083
Sex −10.311 5.715 0.094
Baseline 25(OH)D 0.172 0.094 0.090
Switched memory 
(SM) B cells (%B 
cells)
Phototherapy −3.56 1.975 0.09 −4.686 2.169 0.050
Age 0.053 0.141 0.712
Sex 2.706 2.272 0.255




Phototherapy −2.844 2.777 0.321 −3.678 3.486 0.311
Age 0.108 0.212 0.617
Sex 1.266 3.437 0.719




Phototherapy 0.38 1.515 0.805 0.189 1.912 0.923
Age 0.036 0.126 0.777
Sex 0.178 1.983 0.930
Baseline 25(OH)D −0.03 0.033 0.384
Table 6. Changes from baseline cell frequencies at the 3 month time point. Results were obtained using linear 
regression models. No statistically significant p-values were obtained. *Table shows unstandardised coefficients. 
All models were adjusted for participant’s baseline cell frequencies. ^Model 1 = linear regression for effects of 
phototherapy (categorical variable) adjusted for baseline cell frequencies. #Model 2 = linear regression adjusted 
for the baseline levels of cell frequencies as a covariable, as well as age (years), sex, and baseline serum 25(OH)D 
levels (nmol/L).
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receptors such as CD84 and TLRs24. In people with MS, peripheral blood naïve B cell frequencies are significantly 
increased during remission25 and upon effective disease treatment26, and naïve B cells from people with MS pro-
duce more IL-10 than memory B cells27. It is possible that IL-10 producing Bregs, which protect against EAE in 
the mouse model of MS28, and are induced by UVR in mice29,30, expand within the naïve B cell subset during pho-
totherapy. Further investigation of the B cell compartment may reveal whether the functional activities or survival 
and/or proliferation of specific B cell subsets are altered by phototherapy in CIS. Effects on the naïve and/or SM 
B cell populations are also reported for DMTs in MS26,31,32. Given the proposed roles of B cells in contributing 
to MS progression through both antibody-dependent and -independent effects33,34, this study suggests that the 
reduction in frequencies of memory B cells associated with narrowband UVB phototherapy could have benefits 
for people with CIS.
There were lower frequencies of classical monocytes (CD14+CD16−) after phototherapy compared with 
control participants at 1–2 M and 1–3 M in mixed effects models, and at 2 M specifically using linear regres-
sion. In addition, there were higher intermediate monocyte frequencies (CD14+CD16int) from 1–2 M in mixed 
Figure 2. Percent shift from individual baseline frequencies of non-suppressive FrIII Treg cells 
(%FoxP3 + Tregs). Cells were examined in individuals from control (◻) and phototherapy (•) groups. The 
group means and SEM are shown. Longitudinal effects of phototherapy detected in mixed effects models 
including data from 1–3 M are described by text (p = 0.044).
Figure 3. Percent shift from individual baseline cell frequencies of (a) naïve, and (b) switched memory (SM) 
B cell subsets, measured in individuals from control (◻) and phototherapy (•) groups. The group means and 
SEM are shown. Statistical outcomes from linear regression are shown above the 2 M time point where relevant, 
where * indicates a significant difference between the control and phototherapy groups at that time point 
(p < 0.05) in at least one data model. Longitudinal effects of phototherapy treatment detected in mixed effects 
models including data from 1–2 M and from 1–3 M are shown, with significant p-values and the sample time 
points included described by text.
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effects models and at 2 M using linear regression in phototherapy-treated individuals compared with controls. 
These findings support a previous report that monocyte expression of CD16 increased following repeated UVB 
exposure in healthy donors35. In people with untreated MS, CD16+ monocytes were reported to have higher 
expression of a number of activating receptors, including the FcγRI (CD64), and secrete less IL-10 upon ex vivo 
activation compared with classical monocytes36. However, following in vivo or in vitro exposure of monocytes to 
DMTs, the CD16int monocyte population is reported to expand, produce the most IL-10, and increase phago-
cytic activity37,38, becoming functionally similar to intermediate monocytes in healthy individuals39. Therefore, 
although increased non-classical monocyte frequencies (CD14loCD16+) are a biomarker of active MS disease40, 
intermediate monocytes may actively contribute to suppressing inflammation following successful treatment of 
MS. Consequently, the higher intermediate monocyte frequency observed after phototherapy in this study sug-
gests potential clinical benefits in MS, and as such, functional assays or additional markers on monocytes should 
be investigated in future.
UVR-induced increases in Tregs and/or FoxP3 expression by Tregs have been reported in multiple studies in 
healthy individuals, and those with skin conditions9,11,12. However, in the current study, no increase in circulating 
FoxP3+ or traditional CD4+CD25+CD127lo Tregs was detected in association with phototherapy. In one prior 
trial of narrowband UVB phototherapy in patients with skin disease, the frequency of circulating FoxP3+ Tregs 
increased in correlation with serum 25(OH)D levels, up to approximately 50 nmol/L9. The individuals in our 
study had much higher serum 25(OH)D levels at the time of their enrolment, and therefore, it could be speculated 
that in our participants, UV-inducible expansion of FoxP3+ Tregs had already plateaued. On the other hand, the 
absence of a UVB-induced expansion of Tregs in the current study and in a prior study of vitamin D-deficient MS 
patients10 suggests a disease-specific inability to induce FoxP3+ Tregs following UVB exposure and/or increased 
serum 25(OH)D levels. Although phototherapy was not associated with changes in the proportions of FoxP3+ 
Tregs expressing Helios in the present study, our finding of a proportional increase in the FrIII Treg fraction is 
consistent with the previously reported UVB-induced expansion in the proportions of Helios- Tregs in people 
with MS10, since FrIII has the highest proportion of Helios- cells15. FrIII Tregs exhibit pro-inflammatory rather 
than suppressive activity compared with FrI and FrII Tregs, and FrIII contains the greatest proportion of CCR6+ 
T helper (Th)17-like and CCR6+CXCR3+ Th17.1-like Tregs15,41. Preferential transmigration of the latter cells 
into the central nervous system (CNS) in patients with CIS reduces the frequency of these cells in the circulation 
and is associated with more rapid conversion from CIS to clinically definite MS42. Therefore, it is possible that 
increased frequencies of FrIII Tregs following phototherapy in this study were a result of decreased migration of 
these cells into the CNS, although no corresponding CNS samples are available to investigate this hypothesis in 
these participants.
No effect of phototherapy on DCs or NK cells were detected in this study. Narrowband UVB therapy over four 
weeks in patients with psoriasis was previously associated with decreased frequencies of circulating CD56 + NK 
cells7, and another study found that the numbers of CD1c- DC decrease in the skin after UVB treatment21. It is 
possible that the small sample size available limited our power to detect changes in some cell types. Despite this, 
changes that were detected in cell populations associated with phototherapy were often repeated in independent 
statistical analyses, with biological findings reflecting the expected pattern over time, where the largest difference 
Figure 4. Percent shift from individual baseline cell frequencies of (a) classical and (b) intermediate monocyte 
subsets, measured in individuals from control (◻) and phototherapy (•) groups. The group means and SEM are 
shown. Statistical outcomes from linear regression are shown above the 2 M time point where relevant, where  
* indicates a significant difference between the control and phototherapy groups at that time point (p < 0.05) in 
at least one data model. Longitudinal effects of phototherapy detected in mixed effects models including data 
from 1–2 M and from 1–3 M are shown, with significant p-values and the sample time points included described 
by text.
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between treatment groups was at the completion of phototherapy at the 2 month time point. Therefore, despite 
the need to recognise the limitations associated with the small sample size43, the conclusions regarding cells 
changed by phototherapy are logically and statistically supported by the data available. However, more studies are 
needed to determine the precise effect size of circulating cellular responses to phototherapy, and other potential 
effects on cell subsets that we may not have detected.
In this study, cellular profiles were examined in blood samples from participants in the PhoCIS trial for which 
the clinical outcomes have been previously published17. In summary, by 12 M, three of ten participants receiving 
narrowband UVB phototherapy had not converted from CIS to MS whereas all nine participants who did not 
receive phototherapy converted. In this report, we have pooled changes in cell phenotypes from all ten partici-
pants receiving narrowband UVB phototherapy, and all nine not receiving phototherapy. For the three partici-
pants who had not converted to MS by 12 M, a longitudinal analysis of their cells from baseline to 3 M was also 
performed as any consistent changes may help us determine the changes potentially responsible for the beneficial 
effects of narrowband UVB phototherapy. Although we examined the pattern of cell changes in these three indi-
viduals, and one of them had the largest increase in naïve B cells of the cohort after phototherapy, there was no 
clear and consistent pattern of cell changes in blood from this group of three compared with the individuals who 
received phototherapy but who converted to MS. Furthermore, there were not enough participants to make valid 
statistical comparisons between the converters and non-converters, but this could be investigated in future in a 
larger trial.
Inter-individual differences in baseline serum 25(OH)D levels were accounted for in the analyses presented 
here. Higher baseline serum 25(OH)D was associated with increased naïve B cell frequency in multiple analyses, 
and lower SM B cell frequency in the 1–3 M mixed effects model. The effect of baseline 25(OH)D was detected 
regardless of phototherapy, although for naïve B cells and SM B cells, the effect of phototherapy was larger than 
that of 25(OH)D (estimates of effect sizes as shown in Tables 3 and 4). All individuals had clinically sufficient 
levels of 25(OH)D at the time of baseline blood sample collection, and there was no difference between groups 
in serum 25(OH)D at baseline17. In vitro, a number of effects of 1,25(OH)2-vitamin D3 on B cells have been 
observed44, including inhibition of memory B cell differentiation from naïve cells45. However, in two previous 
clinical trials of high dose vitamin D supplementation (≥10,000 IU/day) in people with MS, no effects on naïve 
B or other B cell frequencies were observed46,47, but in the study of Sotirchos et al., wherein participants received 
20,000 IU/day for 6 months, reductions in IL-17+ and effector memory CD4+ T cells were reported after the 
intervention47. The scale of the effect of phototherapy on B cell frequencies relative to baseline 25(OH)D, particu-
larly when all participants had clinically sufficient serum 25(OH)D levels, suggest that vitamin D-independent 
effects contributed to the effects on B cell frequencies observed here. However, this study was not designed to 
resolve whether effects of narrowband UVB phototherapy on PBMC were independent of vitamin D specifically.
In summary, this study expands upon the known biological effects of low dose UVB radiation in humans, 
and provides data on the short-term effects of narrowband UVB treatment on a new patient population, 
namely, people with high-risk CIS. Despite an earlier focus on the contribution of Tregs to MS disease, no 
phototherapy-associated effects on the frequencies of Tregs were detected, and the largest effects associated with 
phototherapy were detected in naïve B cells. B cells are increasingly recognised as playing important roles in the 
pathogenesis of MS and recovery from episodes of demyelination3,26,31,33,44,48. These findings suggest that narrow-
band UVB phototherapy may have positive, albeit short-lived, clinical effects on people with MS, and should be 
investigated further.
Data Availability
The datasets generated during the current study are available from the corresponding author on reasonable re-
quest.
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